IMMX today
$8.66+$0.31 (+3.71%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourExpanding
1 hourStrong Bullish
15 minBullish
5 minSymmetric Triangle
Daily trend turns up above $8.36
Key levels
Resistance$10.36
Resistance$9.10
Support$8.36
Support$7.17
Latest news & SEC filings
ProductImmix Biopharma to present interim NXC-201 trial data at ASH 2026
NewsImmix Biopharma to share NXC-201 data at December hematology conference
All IMMX news →About Immix Biopharma
Immix Biopharma develops cell-based medicines built on chimeric antigen receptor T-cell technology. Its main candidate, NXC-201, is being tested in patients with relapsed or refractory light chain (AL) amyloidosis, a condition where abnormal amyloid protein collects in organs including the heart, kidneys and liver. Trials are underway in the United States and abroad, and the company is also working on earlier-stage cell therapy programs for other serious illnesses.
Based on the company's 10-K filed Mar 25, 2026.
Nasdaq · Healthcare
Immix Biopharma, Inc. (IMMX)
What Is the Price Target for IMMX?
SEPT Low Target
$15.00
SEPT Mid Target
$25.50
SEPT High Target
$30.00
Analyst Consensus
$25.50
Is IMMX a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IMMX.
Start Free Trial →Is IMMX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$21.41
12
Moat Score
NONE
4/9
Piotroski Score
12.5
Altman Z-Score
What Is Smart Money Doing with IMMX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Ng Carey | director | Buy | 6,250 | - | May 22, 2026 |
| Adams Helen C. | director | Buy | 6,250 | - | May 22, 2026 |
| Marquet Magda | director | Buy | 6,250 | - | May 22, 2026 |
| CHANG NANCY T | director | Buy | 6,250 | - | May 22, 2026 |
| Chudnovsky Yekaterina | director | Buy | 6,250 | - | May 22, 2026 |
| BUCHAN JANE | director | Buy | 6,250 | - | May 22, 2026 |
| Hsu Jason | director | Buy | 6,250 | - | May 22, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →IMMX Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-17.11%
FCF Growth YoY
-56.4%
Revenue Trend
UNKNOWN
Dark Pool Trades for IMMX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for IMMX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:26:10 | $8.66 | 13,609 | $$118K | BUY |
| 21:00:41 | $8.66 | 1,849 | $$16K | SELL |
| 21:00:40 | $8.66 | 12,112 | $$105K | SELL |
| 20:56:05 | $8.67 | 3,000 | $$26K | SELL |
| 20:54:19 | $8.64 | 1,400 | $$12K | SELL |
5 dark pool trades shown · $$277K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Immix Biopharma, Inc. (IMMX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IMMX — frequently asked questions
What is IMMX stock price today?
Immix Biopharma, Inc. (IMMX) is at $8.66, up 3.71% (+$0.31) at the Nov 11, 2026 close.
Why is IMMX stock moving today?
Latest IMMX news — Nov 4, 2026: Immix Biopharma to present interim NXC-201 trial data at ASH 2026 · Nov 4, 2026: Immix Biopharma to share NXC-201 data at December hematology conference
What is the IMMX price target?
The average analyst price target for IMMX is $25.50, ranging from $15 to $30, based on 6 analysts. Latest: Needham maintains on Sep 29, 2026.
What do analysts rate IMMX?
Analyst ratings for IMMX: 0 Buy, 7 Hold, 0 Sell — consensus Hold.
Did IMMX beat earnings?
IMMX last reported on Aug 7, 2026: EPS -$0.18 vs -$0.17 expected — a miss of 5.0%.
What are IMMX support and resistance levels?
Support: $8.36, $7.17, $6.02. Resistance: $9.10, $10.36, $11.75.
What are insiders doing with IMMX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on IMMX?
Nov 4, 2026: Immix Biopharma to present interim NXC-201 trial data at ASH 2026 · Nov 4, 2026: Immix Biopharma to share NXC-201 data at December hematology conference